Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with AMD
Antioxidant multivitamin and mineral supplement probably leads to lower progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Quality of life · people with AMD
1 finding from 1 review
Adverse effects · people with AMD
Antioxidant multivitamin and mineral supplement may leads to lower adverse effects compared with placebo or no treatment (low certainty).
1 finding from 1 review
Resource use and costs · people with AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression to late AMD (neovascular AMD, geographic atrophy or both) · people with AMD
Lutein with or without zeaxanthin showed no clear difference in progression to late AMD (neovascular AMD, geographic atrophy, or both) compared with placebo (low certainty).
1 finding from 1 review
Progression to neovascular AMD · people with AMD
Lutein with or without zeaxanthin showed no clear difference in progression to neovascular AMD compared with placebo (low certainty).
1 finding from 1 review
Glaucoma progression at 12 months, measured by additional visual field defects · people with primary angle‐closure suspect
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean change in IOP measured in mmHg 12 months postintervention · people with primary angle‐closure suspect
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Gonioscopic findings · people with primary angle‐closure suspect
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Need for additional surgery: proportion of participants who received additional surgery to control IOP at 1 year · people with primary angle‐closure suspect
Iridotomy showed no clear difference in need for additional surgery: proportion of participants who received… compared with no iridotomy (low certainty).
1 finding from 1 review
RR 0.5 [0.05, 5.5]
Studies not reported
Low
Mean number of antiglaucoma medications at 1‐year · people with primary angle‐closure suspect
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life measures · people with primary angle‐closure suspect
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with primary angle‐closure suspect
Iridotomy showed no clear difference in adverse events compared with no iridotomy (low certainty).
1 finding from 1 review
RR 13.7 [0.73, 230.42]
Studies not reported
Low
Intervention not reported
Undercorrected vs fully corrected spectacles · children with myopia (nearsightedness)
1 finding from 1 review
Intervention not reported
Systemic 7‐methylxanthine vs placebo · children with myopia (nearsightedness)
1 finding from 1 review
Intervention not reported
Timolol drops vs no drops · children with myopia (nearsightedness)
1 finding from 1 review
Intervention not reported
Atropine plus multifocal spectacles vs placebo plus SVLs · children with myopia (nearsightedness)
1 finding from 1 review
Intervention not reported
Atropine plus bifocal spectacles vs cyclopentolate plus SVLs · children with myopia (nearsightedness)
1 finding from 1 review
Intervention not reported
Bifocal spectacles vs SVLs with timolol drops · children with myopia (nearsightedness)
1 finding from 1 review
Intervention not reported
Tropicamide plus bifocal spectacles vs SVLs · children with myopia (nearsightedness)
1 finding from 1 review